APA Comments on FDA's First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder (PR Newswire via Yahoo! News)
The American Psychiatric Association (APA) applauds the U.S. Food and Drug Administration (FDA) for its review of scientific evidence that led to the approval of a new treatment for two severe psychiatric disorders in children. The APA is pleased that the approvals are a result of the federal Best Pharmaceuticals for Children Act (BCPA), which was designed to encourage research that leads to ...

Aclasta Receives US FDA Approval As First And Only Once-Yearly Treatment For Women With Postmenopausal Osteoporosis (Medical News Today)
Aclasta (zoledronic acid 5mg) has been approved by the US Food and Drug Administration (FDA) under the brand name Aclasta Injection as the first and only once-yearly medicine for postmenopausal osteoporosis, offering an important new approach to the treatment of a bone disease affecting eight million women in the US1. [click link for full article]